Non-invasive bladder urothelial carcinoma

This large trial is testing whether a blood test that looks for tumor DNA can help decide who needs immunotherapy after surgery for muscle-invasive urothelial cancer. About 992 participants will be assigned to different treatment plans based on their blood test results. The goal …

This phase III trial tests whether giving the drug Alpha1H directly into the bladder before standard surgery lowers the risk of cancer returning in adults with low- to intermediate-risk non-muscle-invasive bladder cancer. Participants are randomly assigned to receive either six A…

This study tests a healthy eating program that encourages people with early-stage bladder cancer to eat more cruciferous vegetables like broccoli, kale, and cabbage. These veggies contain natural compounds that may help fight cancer cells. Researchers want to see if this diet cha…

This study tests whether adding an experimental treatment (V940) to standard BCG therapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning. About 308 adults will be randomly assigned to get either V940 plus BCG or BCG alone.…

This study tests two drugs, durvalumab and monalizumab, given together to people with a type of bladder cancer that has not gotten better with standard treatment. The goal is to see if the combination can make the cancer disappear or stop it from growing. About 60 adults will tak…

People with high-grade non-muscle-invasive bladder cancer often receive BCG immunotherapy, but some cancers stop responding. The standard next step is surgery to remove the bladder, which many patients cannot or choose not to have. This trial tests whether radiation to the whole …

This program provides early access to cretostimogene grenadenorepvec, a virus-based therapy, for patients with non-muscle invasive bladder cancer that has not responded to standard BCG treatment. Eligible participants have a specific type of bladder cancer (CIS with or without hi…

This Phase 2 trial tests an oral drug called TYRA-300 in 90 adults with a low-grade, intermediate-risk bladder cancer that has not invaded muscle. The cancer must have a specific genetic change (FGFR3 alteration). Participants take a daily tablet for up to 2 years. The main goal …

This phase 3 trial is testing whether adding an experimental drug called SHR-1501 to the standard BCG therapy can improve outcomes for people with a high-risk form of bladder cancer that has not spread into the muscle wall. Participants must have had all visible tumors removed be…

This study tests a new drug called PF-08052667 for adults with a type of bladder cancer that hasn't spread into the muscle layer but is likely to return. The drug is given directly into the bladder, sometimes with other medicines like BCG or sasanlimab. The trial has three parts …

This phase II trial compares two treatments for high-grade T1 bladder cancer that hasn't spread. One group gets the immunotherapy drug pembrolizumab plus radiation, while the other gets standard chemotherapy (cisplatin, gemcitabine, 5-fluorouracil, or mitomycin-C) plus radiation.…

This phase 3 trial tests a gene therapy called nadofaragene firadenovec against simply watching and waiting in people with intermediate-risk non-muscle invasive bladder cancer. The study will enroll 454 participants who have had a tumor removed. The goal is to see if the gene the…

This phase 2 trial tests a treatment called NDV-01 KIT for people with high-grade non-muscle invasive bladder cancer (NMIBC). The treatment is a gel containing two chemotherapy drugs, gemcitabine and docetaxel, which is placed directly into the bladder through a catheter. Partici…

This phase 3 trial tests a new drug, TAR-210 (erdafitinib), placed directly into the bladder, against standard chemotherapy for people with a high-risk type of bladder cancer that has come back after BCG treatment. The study includes 220 adults whose tumors have certain FGFR gene…

This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with a type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder through a catheter. The main goals are to find the safest dose and see if people can toler…

This study is tracking 150 people with early-stage bladder cancer who are receiving TAR-200, a treatment placed directly into the bladder. Researchers want to see how long it takes for the cancer to come back or get worse in real-world settings, not just in controlled trials. The…

This study compares a new drug delivery system (TAR-210) that releases erdafitinib directly into the bladder versus standard chemotherapy for people with intermediate-risk non-muscle invasive bladder cancer that has certain genetic changes (FGFR alterations). About 641 participan…

This phase 2 study is testing a new treatment called TARA-002 for people with a type of high-grade bladder cancer that hasn't spread into the muscle. The treatment is given directly into the bladder through a catheter once a week for 6 weeks. The study will include about 131 adul…

This phase 3 trial tests whether a new drug, TARA-002, works better than standard chemotherapy for a type of early-stage bladder cancer. About 284 adults who have not received BCG therapy will be randomly assigned to receive either TARA-002 or chemotherapy directly into the bladd…

This study compares different FDA-approved drugs for a type of bladder cancer that hasn't spread into the muscle. About 125 adults whose previous treatment with BCG didn't work will receive either a newer gene therapy or standard drugs. The goal is to see which treatment better p…

This phase II trial is testing an experimental biologic called T3011, given directly into the bladder, for people with high-risk non-muscle-invasive bladder cancer that has not responded to BCG therapy or chemotherapy. The study aims to see if this treatment can shrink or elimina…

This early-stage trial tests a new drug called PPM, which are tiny particles loaded with the chemotherapy drug paclitaxel and coated with a molecule (PLZ4) that helps them target bladder cancer cells. The drug is given directly into the bladder through a catheter once a week for …

This early-stage study tests a new drug called 2141-V11 in people with a type of bladder cancer that hasn't responded to standard therapy. The drug is given directly into the bladder through a catheter or by injection into the tumor. The main goal is to see if it's safe and to fi…

This study tests a new drug called EG-70 (detalimogene) for a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). The drug is given directly into the bladder through a catheter. The trial includes patients whose cancer did not respond to standard BCG therapy…

This phase 3 trial is testing a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or combined with chemotherapy or immunotherapy. It is for people with a type of bladder cancer that has not responded to standard BCG therapy. The study aim…

This phase 3 trial tests whether adding the chemotherapy drug gemcitabine to standard BCG therapy can better prevent high-grade bladder cancer from coming back. About 330 people with recurrent non-muscle invasive bladder cancer will receive either BCG alone or BCG plus gemcitabin…

This trial tests two different drug combinations given directly into the bladder for people with a type of bladder cancer that has not responded to the standard BCG therapy. Participants are randomly assigned to receive either gemcitabine plus docetaxel or gemcitabine plus mitomy…

This trial tests whether an oral herbal supplement called LCS103 can help prevent non-muscle invasive bladder cancer from recurring after surgery. Sixty adults who have had their bladder tumors completely removed will take either LCS103 plus standard care or standard care alone f…

This study tests whether adding an immunotherapy drug (toripalimab) to standard BCG therapy can help people with high-risk bladder cancer avoid bladder removal. About 31 participants will receive the combination after surgery. The main goal is to see if the cancer disappears with…

This study tests whether adding the drug disitamab vedotin to standard BCG therapy can help keep high-risk, early-stage bladder cancer from returning. It includes 182 adults whose cancer has been surgically removed but is at high risk of coming back. Participants will receive eit…

This Phase 3 trial is testing whether a combination of an experimental drug (SHR-1501) plus the standard immunotherapy BCG works better than chemotherapy for people with a type of bladder cancer (papillary-only NMIBC) that no longer responds to BCG alone. The study plans to enrol…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This study investigates whether combining the immunotherapy drug durvalumab with a cancer vaccine (S-488210/S-488211) can help people with a type of bladder cancer that has not responded to standard treatment. The trial includes adults with high-risk non-muscle invasive bladder c…

This phase II trial is testing a combination of two drugs—disitamab vedotin given through a vein and mitomycin C placed directly into the bladder—in 30 people with a specific type of non-muscle-invasive bladder cancer that has a protein called HER2. The goal is to see if this tre…

This phase 2 trial tests a two-drug combination (mitomycin-C and gemcitabine) given directly into the bladder for people with high-risk bladder cancer that did not respond to BCG therapy. The study will enroll 82 participants to see if this sequential treatment can prevent cancer…

This study tests a new treatment for people with a high-risk type of bladder cancer that did not get better after standard BCG therapy. The treatment combines two chemotherapy drugs placed directly into the bladder with an immunotherapy drug given through a vein. The goal is to s…

This study tests a new drug called STM-416 that is applied directly to the bladder during surgery to remove tumors. It is for people with a type of bladder cancer that keeps coming back. The goal is to see if the drug is safe and can help keep the cancer from returning. About 75 …

This study tests whether a urine DNA test can help guide when to stop immunotherapy in people with a very high-risk type of bladder cancer that cannot be fully removed by surgery. About 53 participants will receive immunotherapy and then be monitored with urine tests and scans. I…

This expanded access program offers a modified tuberculosis vaccine (recombinant BCG) to people with non-muscle invasive bladder cancer who cannot join a clinical trial. The treatment is given directly into the bladder and aims to control the disease. It is only for patients who …

This phase 2 trial is testing a treatment called cretostimogene grenadenorepvec, a modified virus designed to infect and destroy cancer cells, in 16 people with high-risk bladder cancer that has not responded to standard BCG therapy. The study aims to see if the treatment can mak…

This phase 2 trial is testing whether two chemotherapy drugs, gemcitabine and docetaxel, given directly into the bladder can treat high-risk bladder cancer that did not respond to standard BCG therapy. About 174 adults will receive weekly treatments for 6 weeks, then monthly for …

This early-stage trial is testing a new version of the BCG therapy, made from a genetically modified bacterium, for people with non-muscle invasive bladder cancer (NMIBC) who have not received BCG before. The treatment is given directly into the bladder through a catheter. The st…

This phase 3 trial is testing a new version of the BCG vaccine, called Verity-BCG, against the standard BCG treatment (OncoTICE) in 540 people with intermediate or high-risk non-muscle invasive bladder cancer who have not received BCG before. The goal is to see if Verity-BCG is a…

This early-stage trial tests a new treatment called PLZ4-coated paclitaxel-loaded micelles (PPM) for people with non-muscle invasive bladder cancer that has come back or not responded to standard therapy. PPM is a nanoparticle designed to deliver chemotherapy directly to tumor ce…

This early-stage trial tests a modified virus called KD01, given directly into the bladder, to see if it is safe and can fight bladder cancer. The study includes 29 patients with either high-risk non-muscle-invasive bladder cancer or muscle-invasive bladder cancer. Some patients …

This study compares two approaches for treating non-muscle invasive bladder cancer. The standard approach uses two surgeries: one to remove the tumor and a second to check for leftover cancer. The new approach uses a single, enhanced surgery with a special dye and light to better…

This study tests whether adding the drug bicalutamide to standard BCG therapy can help prevent bladder tumors from returning in men with non-muscle invasive bladder cancer. About 160 participants will be randomly assigned to receive either BCG alone or BCG plus bicalutamide. The …

This study tests a new drug called Ruvidar, given directly into the bladder, for people with a type of bladder cancer that did not respond to or could not tolerate standard BCG therapy. About 90 adults will receive up to three treatment sessions. The main goal is to see if the dr…

This study looks at whether giving patients IV fluids at home for four weeks after bladder cancer surgery can lower the chance of needing to go back to the hospital. About 130 adults having this surgery will be randomly assigned to either get the usual care or the usual care plus…

This study tests whether a drug treatment (chemoablation) can replace surgery for people with a common, recurring type of bladder cancer. About 272 adults with small, low-grade tumors that came back will either get the drug or standard surgery plus additional therapy. The goal is…

This early-stage trial is testing a new drug called RAG-01 in 72 people with a type of bladder cancer that has not responded to standard therapy. The drug uses a small RNA molecule to try to control the cancer. The main goals are to check safety and find the right dose, while als…

This study tests whether a simple urine test (Bladder EpiCheck) can safely replace some of the invasive cystoscopy procedures used to monitor non-muscle invasive bladder cancer. About 240 adults with low-grade intermediate-risk bladder cancer will be followed to compare quality o…

This study collects video recordings and data from 500 patients undergoing blue light cystoscopy, a procedure where a drug makes cancer cells glow. The goal is to train an artificial intelligence (AI) algorithm to detect bladder lesions in real time, helping doctors make more acc…

This study looks at whether a simple urine test for tumor DNA can tell which bladder cancer patients truly need a second surgery after their first tumor removal. About 196 adults with non-muscle-invasive bladder cancer will be randomly assigned to have their repeat surgery decisi…

This study is testing a new urine test that aims to predict whether bladder cancer patients will respond well to a standard treatment called BCG. Currently, about half of patients do not respond to BCG, leading to extra treatments or bladder removal. The test looks for specific m…

This study compares CT and MRI scans to see which more accurately determines if bladder cancer has spread into the muscle layer. About 150 adults with newly diagnosed bladder cancer will receive both scans before standard surgery. The results will be checked against tissue sample…

This study is testing whether a simple urine test that looks for cancer DNA can help decide when patients with high-risk bladder cancer need a cystoscopy (a camera exam of the bladder). Cystoscopy is effective but uncomfortable and can cause infections. The goal is to safely redu…

This study is testing BCDx, a urine-based test designed to detect the return of non-muscle invasive bladder cancer (NMIBC) earlier and without a scope. Researchers will enroll 500 people with a history of NMIBC and compare the test's accuracy to standard cystoscopy. If it works, …

This study is testing a new urine test that might find returning bladder cancer earlier and more accurately than current urine tests. The goal is to see if this test can reduce the need for cystoscopy, a procedure where a tiny camera is inserted into the bladder. About 300 adults…

This registry study is gathering information on how well blue light cystoscopy with Cysview detects bladder cancer compared to standard white light cystoscopy. About 4400 adults with suspected or known non-muscle invasive bladder cancer will take part. The goal is to see if the b…

This study is testing whether a combined blood and urine DNA test can accurately detect muscle-invasive bladder cancer in patients scheduled for bladder removal surgery. Researchers will compare the test results with the actual findings from surgery. The goal is to see if this no…

This study is testing whether a simple urine test that looks for tumor DNA can help some bladder cancer patients safely have fewer cystoscopy exams. Cystoscopy involves inserting a camera into the bladder and can be uncomfortable. The trial will enroll 56 high-risk patients who h…

This study is testing whether dutasteride, a pill already used for prostate issues, can stop low-grade bladder cancer from coming back. About 95 adults with this type of bladder cancer will take the drug daily. The goal is to see if it reduces the need for repeated surgeries and …

This study tests whether adding Hydeal Cyst® instillations can reduce lower urinary tract symptoms in people receiving standard chemotherapy or immunotherapy for non-muscle invasive bladder cancer. About 200 participants will receive either BCG or MMC, and half will also get Hyde…

This study compares a home-based physical activity program delivered through the ExerciseRx app to health education alone in 100 adults with non-muscle invasive bladder cancer. Participants will use a Fitbit to track steps, and the app will set personalized goals and provide enco…

This study tests whether giving chemotherapy directly into the bladder at home is safe and acceptable for people with non-muscle invasive bladder cancer. About 40 participants will receive their usual medications—such as BCG, gemcitabine, docetaxel, or mitomycin—at home instead o…

This study looks at 56 adults with non-muscle-invasive bladder cancer who receive BCG therapy, a standard treatment that often causes painful bladder symptoms. Researchers want to see if giving Blad-Care (a gel that restores the bladder's protective lining) early during BCG treat…

This study is testing whether an artificial intelligence (AI) tool can analyze digital images of bladder tumor tissue to predict how well patients will respond to standard treatments like BCG therapy or chemotherapy. The research involves 600 people with intermediate or high-risk…

This study is collecting blood, urine, and tumor tissue samples from about 400 adults with suspected high-risk non-muscle invasive bladder cancer. The goal is to find biological markers that could lead to new tests for detecting and monitoring this type of cancer. Participants wi…

This study looks at two common treatments for a type of bladder cancer that keeps coming back: treatments that keep the bladder (like medicine placed directly into the bladder) versus surgery to remove the bladder. The goal is to see which option is better for patients' wallets, …

This early-stage trial is testing whether bicalutamide, a drug typically used for prostate cancer, can change a protein linked to bladder cancer growth. Researchers will compare men with non-muscle invasive bladder cancer who take the drug to those who don't. The goal is to see i…

This study explores whether giving BCG therapy for non-muscle invasive bladder cancer at home is feasible and effective. It includes two groups: one to understand barriers to treatment compliance, and another to test a home BCG program with a chatbot that tracks symptoms and qual…

This study is a registry that collects information on how doctors treat and monitor patients with non-muscle-invasive bladder cancer in France. Researchers will track up to 8,000 adults to see how often cancer returns or worsens, and to test the accuracy of urine biomarker tests.…

This study collects urine samples from 1000 adults who may have bladder cancer or are being monitored for it. Researchers will use the samples to improve a test called Bladder EpiCheck. Participants provide one urine sample and share basic health information. The goal is to make …

This study from the University of Zurich is looking at how tiny organisms (microbes) and the immune system interact in the bladder. Researchers will collect samples from 800 adults with various urinary conditions, including infections, bladder pain, and overactive bladder, as wel…

This study tests whether a patient's position (lying down, sitting up, or moving freely) affects how long the BCG medicine stays in the bladder during treatment for non-muscle invasive bladder cancer. Researchers will measure dwell time in 40 patients under three different positi…

This study aims to understand the sexual health challenges faced by bladder cancer patients and develop a support program tailored to their needs. Researchers will interview 30 patients to learn about their experiences and preferences for professional help. The goal is to create …

This study looks at how the standard BCG treatment for non-muscle invasive bladder cancer may affect patients' mood. Researchers will collect urine and blood samples to measure immune responses, and participants will fill out mood questionnaires and daily diaries. The goal is to …